What is hidradenocarcinoma?
Hidradenocarcinoma is a rare skin cancer that grows from a sweat gland. It is the malignant (cancerous) form of a hidradenoma, a common harmless sweat gland lump that is also called a nodular or clear cell hidradenoma.
It belongs to the adnexal carcinomas, a group of cancers that arise from skin structures such as sweat glands, hair follicles and oil glands.
Hidradenocarcinoma usually appears as a firm, slowly enlarging lump in or under the skin. It is most common on the head and neck, but it also occurs on the trunk, arms and legs (Gao et al., 2022). It mostly affects adults in their 50s to 70s, with an average age of about 60 (Kent et al., 2024).
It can develop on its own or, rarely, from a long-standing benign hidradenoma. Because it looks like many common skin lumps, it is usually diagnosed only after removal and examination under the microscope.
Older reports described hidradenocarcinoma as a very aggressive cancer, with high rates of recurrence and spread. More recent, larger studies suggest that most people do well after complete surgery, although the cancer can come back or spread to lymph nodes in a minority of cases (Gao et al., 2022).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Malignant sweat gland (adnexal) carcinoma of the skin |
| How common | Rare; a small fraction of all skin cancers |
| Typical age | Average about 60; range from young adults to the very elderly |
| Sex | Slightly more common in men in some series |
| Common sites | Head and neck (about 4 in 10); trunk, arms and legs |
| Appearance | Firm, red, purple or skin-coloured lump, sometimes ulcerated |
| Main treatment | Wide local excision or Mohs surgery |
| Typical spread | Nearby skin, lymph nodes; less often lungs, bone, liver |
| Outlook | Good for most after complete removal; worse if it has spread |
2. Causes and risk factors
The cause of hidradenocarcinoma is not known. Unlike many skin cancers, it is not clearly linked to sun exposure, and it often occurs on skin that is usually covered.
| Factor | Notes |
|---|---|
| Age | Most people are over 50 |
| Pre-existing hidradenoma | Rarely, a benign hidradenoma turns malignant |
| Weakened immune system | May increase risk, as with other skin cancers |
| Previous radiation | Reported in a few cases |
Gene changes
| Gene change | Notes |
|---|---|
| CRTC1::MAML2 fusion | Common in benign hidradenomas and found in a subset of hidradenocarcinomas (Yoshimi et al., 2017) |
| HER2 (ERBB2) overexpression | Seen in some tumours; may open up targeted treatment options |
| TP53 changes | Found in some tumours |
| PIK3CA and other pathway changes | Reported in a minority |
These changes arise only in the tumour and are not inherited. Specialised tests for gene changes can help pathologists confirm that a tumour comes from a sweat gland and separate it from other cancers (Macagno et al., 2022).
Hidradenocarcinoma and related sweat gland tumours
| Tumour | Behaviour | Notes |
|---|---|---|
| Hidradenoma | Benign | Common, slow-growing lump; often solid and cystic |
| Poroma | Benign | Sweat duct tumour, often on the palms or soles |
| Hidradenocarcinoma | Malignant | The cancerous counterpart of hidradenoma |
| Porocarcinoma | Malignant | The cancerous counterpart of poroma |
| Microcystic adnexal carcinoma | Malignant, locally aggressive | Usually on the face; spreads along nerves |
| Mucinous carcinoma of the skin | Malignant, low grade | Usually around the eyes |
3. How does it look
On the skin
| Feature | Description |
|---|---|
| Shape | A single, firm, raised lump or nodule, sometimes a deeper swelling |
| Colour | Skin-coloured, red, pink, purple or blue |
| Surface | Smooth, shiny, crusted or ulcerated |
| Size | Usually 1-5 cm, sometimes larger |
| Growth | Often slow, sometimes with a recent spurt of growth |
| Discharge | May ooze clear fluid or bleed |
| Feel | Firm or rubbery; may feel partly fluid-filled |
On scans
Ultrasound may show a solid and cystic lump in the skin and the fat beneath. CT, MRI or PET-CT are used if the tumour is large or if spread to lymph nodes or other organs is suspected.
Under the microscope
| Feature | Description |
|---|---|
| Structure | Nodules and sheets of tumour cells, often with cystic spaces |
| Cells | Clear cells with pale cytoplasm, and polygonal cells with pink cytoplasm |
| Ducts | Small duct-like spaces lined by tumour cells |
| Malignant features | Infiltrative edges, abnormal nuclei, many mitoses, necrosis, invasion of nerves or vessels |
| Comparison with hidradenoma | Hidradenoma is well circumscribed with no infiltration and few mitoses |
| Special stains | Keratins, EMA and CEA in duct structures; p63 often positive; HER2 positive in some |
Telling hidradenocarcinoma apart from a benign hidradenoma or from cancer that has spread to the skin from another organ, such as the breast or kidney, can be difficult. Review by an expert dermatopathologist is recommended (Ahn and Sangüeza, 2019).
4. Symptoms
Hidradenocarcinoma usually causes few symptoms apart from the lump.
Common symptoms
- A firm lump in or under the skin
- A lump that is growing, sometimes after years of being stable
- Bleeding or oozing from the lump
- Ulceration or a sore that does not heal
- Tenderness or pain in some people
- Redness or discoloured skin over the lump
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Nearby skin | New small lumps around the scar |
| Lymph nodes | Swollen lumps in the neck, armpit or groin |
| Lungs | Cough, breathlessness, chest pain |
| Bone | Bone pain |
| Liver | Tummy discomfort, jaundice (rare) |
When to seek medical advice
See a doctor or dermatologist about any lump that is new, growing, bleeding, ulcerated or that has changed after being stable for a long time. Many skin lumps are harmless, but a biopsy is the only way to be sure.
5. Diagnosis
| Test | Purpose |
|---|---|
| Skin examination | Assesses the lump and nearby lymph nodes |
| Biopsy or excision | Removes tissue for diagnosis; excision of the whole lump is often best |
| Immunohistochemistry | Confirms sweat gland origin and excludes other cancers |
| Molecular testing | MAML2 fusion or HER2 testing in selected cases |
| Ultrasound of lymph nodes | Looks for spread, with needle biopsy if suspicious |
| Sentinel lymph node biopsy | Considered for higher-risk tumours |
| CT or PET-CT | For large or high-risk tumours, or if spread is suspected |
| Tests to exclude metastasis | Breast or kidney imaging when the tumour could be a spread from elsewhere |
Why diagnosis is often delayed
Hidradenocarcinoma is often present for months or years before it is diagnosed. There are several reasons:
- It can look like a cyst, lipoma or benign hidradenoma
- It often grows slowly and causes no pain
- A small or shallow biopsy may miss the malignant areas
- It is rare, so it may not be considered at first
For these reasons, any lump that grows, bleeds or changes should be removed or biopsied, and the whole lesion should be examined where possible.
6. Treatment
Treatment is planned by a skin cancer team that may include dermatologists, Mohs surgeons, plastic surgeons, pathologists and oncologists.
Surgery
| Approach | Notes |
|---|---|
| Wide local excision | Removes the tumour with a margin of normal tissue, often 1-2 cm |
| Mohs micrographic surgery | Checks every margin under the microscope; may lower the risk of recurrence and is useful on the face and neck (Kent et al., 2024) |
| Reconstruction | Skin grafts or flaps for larger wounds |
| Re-excision | If margins are not clear |
Lymph nodes
| Situation | Approach |
|---|---|
| High-risk tumour, normal-feeling nodes | Sentinel lymph node biopsy may be offered |
| Cancer in lymph nodes | Lymph node dissection, often followed by radiotherapy |
Sentinel lymph node biopsy explained
| Step | What happens |
|---|---|
| 1. Tracer injection | A small amount of tracer is injected near the tumour site |
| 2. Mapping | A scan and a handheld probe find the first lymph node(s) that drain the area |
| 3. Removal | These sentinel nodes are removed through a small cut, usually at the same time as the main surgery |
| 4. Testing | The nodes are examined for cancer cells |
| 5. Next steps | If cancer is found, further surgery or radiotherapy may be advised |
Radiotherapy
Radiotherapy may be given after surgery for close or positive margins, large or high-grade tumours, nerve invasion, or lymph node spread. It can also be used when surgery is not possible and to relieve symptoms of metastases (Soni et al., 2015).
Treatment of advanced disease
There is no standard drug treatment, because the cancer is rare.
| Option | Notes |
|---|---|
| Chemotherapy | Platinum drugs, capecitabine, taxanes or other regimens; responses are often limited |
| HER2-targeted drugs | Trastuzumab and related drugs have helped some people with HER2-positive tumours |
| Other targeted drugs | Chosen according to gene changes found in the tumour |
| Immunotherapy | Responses to checkpoint inhibitors have been reported in individual patients |
| Clinical trials | Recommended where available |
Side effects
| Treatment | Possible side effects |
|---|---|
| Skin surgery | Pain, scarring, wound infection, slow healing |
| Lymph node surgery | Limb or neck swelling (lymphoedema), numbness, fluid collection |
| Radiotherapy | Skin redness, peeling, tiredness, later skin tightness |
| Chemotherapy | Nausea, tiredness, low blood counts, hair loss, sore hands and feet |
| Targeted and immune therapy | Rash, diarrhoea, heart effects (HER2 drugs), inflammation of organs (immunotherapy) |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Excision or Mohs surgery | Usually a day case under local anaesthetic |
| Larger reconstruction or node surgery | General anaesthetic and a short hospital stay |
| Wound care | Dressings for 1-2 weeks; stitches out after 1-2 weeks |
| Radiotherapy | Short daily sessions on weekdays over 3-6 weeks |
7. Outlook (prognosis)
| Measure | Approximate figures |
|---|---|
| Cancer-specific survival at 10 years | About 90% in a large US registry study (Gao et al., 2022) |
| Spread at diagnosis or later | Over a third of published cases, which may over-represent severe cases (Kent et al., 2024) |
| Local recurrence | Common in older series, especially after incomplete removal |
In the US registry study of 289 people, about 60% were alive at 10 years, but most deaths were from other causes, reflecting the older age of many patients. The cancer itself caused relatively few deaths, and larger tumour size was linked with poorer overall survival (Gao et al., 2022). Older reports of very high recurrence and spread rates may reflect small numbers and severe cases, as well as differences in surgical technique (Gauerke and Driscoll, 2010).
Factors that may be linked with a poorer outlook
- Large tumour size
- Incomplete removal
- High-grade features, such as many mitoses, necrosis or nerve and vessel invasion
- Lymph node or distant spread
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Skin and scar checks | Every 3-6 months for the first 2-3 years, then every 6-12 months |
| Lymph node examination | At each visit |
| Ultrasound or scans | For high-risk tumours or new symptoms |
| Long-term review | Recommended for at least 5 years, as late recurrences occur |
9. Living with hidradenocarcinoma
- Check the scar and surrounding skin monthly for new lumps
- Feel for swollen lymph nodes in the nearest neck, armpit or groin
- Care for your wound and report redness, swelling or discharge
- Ask about lymphoedema care if you had lymph node surgery
- Protect your skin from the sun, especially if you have other skin cancer risk factors
- Keep a photo record of the scar and nearby skin, so changes are easier to spot
- Keep a list of questions for each appointment
- Seek support from rare cancer and skin cancer charities
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is hidradenocarcinoma common? | No, it is a rare skin cancer |
| Is it caused by sweating? | No. It arises from sweat gland cells, but sweating does not cause it |
| Is it inherited? | No |
| Can a benign hidradenoma become cancer? | Rarely, yes. A changing lump should be checked |
| Will I need chemotherapy? | Usually not; surgery is the main treatment |
| Can it come back? | Yes, sometimes, so follow-up is important |
| Is it the same as porocarcinoma? | No. Both are sweat gland cancers, but they come from different parts of the gland |
| Why do I need scans? | Scans check for spread in larger or higher-risk tumours; small, low-risk tumours may not need them |
11. Questions to ask your care team
- Was the tumour completely removed with clear margins?
- Does it have any high-risk features?
- Would Mohs surgery or sentinel lymph node biopsy be helpful?
- Do I need radiotherapy?
- Has the tumour been tested for HER2 or other targetable changes?
- How often will I need check-ups, and for how long?
Resources
- Ahn, C.S. and Sangüeza, O.P. (2019) ‘Malignant sweat gland tumors’, Hematology/Oncology Clinics of North America, 33(1), pp. 53-71.
- Gao, T. et al. (2022) ‘Prognostic analysis of hidradenocarcinoma: a SEER-based observational study’, Annals of Medicine, 54(1), pp. 454-463.
- Gauerke, S. and Driscoll, J.J. (2010) ‘Hidradenocarcinomas: a brief review and future directions’, Archives of Pathology and Laboratory Medicine, 134(5), pp. 781-785.
- Kent, S. et al. (2024) ‘Hidradenocarcinoma: a case series from the Scripps Clinic with a systematic review of the literature’, Dermatologic Surgery, 50(6), pp. 507-511.
- Macagno, N. et al. (2022) ‘Recent advances on immunohistochemistry and molecular biology for the diagnosis of adnexal sweat gland tumors’, Cancers, 14(3), 476.
- Soni, A. et al. (2015) ‘Current management approach to hidradenocarcinoma: a comprehensive review of the literature’, Ecancermedicalscience, 9, 517.
- Yoshimi, K. et al. (2017) ‘Translocation of the MAML2 gene in hidradenocarcinoma’, Journal of Dermatology, 44(8), pp. e190-e191.
- National Cancer Institute (2026) Skin Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/skin-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.